CODEX:Collection of Aflibercept Data in Routine Practice

Trial Profile

CODEX:Collection of Aflibercept Data in Routine Practice

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms CODEX
  • Sponsors Bayer
  • Most Recent Events

    • 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2016 Planned End Date changed from 1 Dec 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top